Loading...
ORIC logo

ORIC Pharmaceuticals, Inc.NasdaqGS:ORIC 株式レポート

時価総額 US$1.4b
株価
n/a
1Y43.6%
7D2.7%
1D1.1%
ポートフォリオ価値
​
表示

ORIC Pharmaceuticals, Inc.

NasdaqGS:ORIC 株式レポート

時価総額：US$1.4b

ORIC Pharmaceuticals（ORIC）株式概要

臨床段階のバイオ医薬品会社であるORIC Pharmaceuticals, Inc.は、米国で癌の耐性メカニズムに対抗する治療法の発見と開発に取り組んでいる。 詳細

ORIC ファンダメンタル分析
スノーフレーク・スコア
評価1/6
将来の成長0/6
過去の実績0/6
財務の健全性6/6
配当金0/6

リスク分析

今後3年間の収益は年平均5.5%減少すると予測されている。

収益が 100 万ドル未満 ( $0 )

現在は利益が出ておらず、今後3年間で利益が出る見込みはない

US市場と比較した過去 3 か月間の株価の変動


ORIC Community Fair Values

Create Narrative

See what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW475,857 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
475,857 investors already sharing narratives
View all narratives

ORIC Pharmaceuticals, Inc. 競合他社

価格と性能

株価の高値、安値、推移の概要ORIC Pharmaceuticals
過去の株価
現在の株価US$13.87
52週高値US$14.93
52週安値US$7.23
ベータ0.97
1ヶ月の変化29.26%
3ヶ月変化74.91%
1年変化43.58%
3年間の変化63.85%
5年間の変化-28.36%
IPOからの変化-46.18%

最新ニュース

Seeking Alpha • Jul 21

ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull Case

Summary ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, with full global rights and royalty-free economics. ORIC’s $419.7M cash position funds operations into 2H 2028, supporting pivotal trial readouts while minimizing dilution via strategic partnerships and disciplined capital allocation. Rinzimetostat’s value is enhanced by a unique royalty-free license and free darolutamide supply from Bayer, maximizing potential post-approval returns. Enozertinib shows promising CNS activity in NSCLC; pivotal updates in 2H 2026 are crucial for confirming its competitive differentiation and registrable profile. Read the full article on Seeking Alpha
分析記事 • Jun 13

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Recent updates

Seeking Alpha • Jul 21

ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull Case

Summary ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, with full global rights and royalty-free economics. ORIC’s $419.7M cash position funds operations into 2H 2028, supporting pivotal trial readouts while minimizing dilution via strategic partnerships and disciplined capital allocation. Rinzimetostat’s value is enhanced by a unique royalty-free license and free darolutamide supply from Bayer, maximizing potential post-approval returns. Enozertinib shows promising CNS activity in NSCLC; pivotal updates in 2H 2026 are crucial for confirming its competitive differentiation and registrable profile. Read the full article on Seeking Alpha
分析記事 • Jun 13

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 22

ORIC Pharmaceuticals: Looking To The Horizon With Pivotal Study Plans

Summary ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, targeting prostate and lung cancer, but remains in very early clinical stages. Financially, ORIC is well-capitalized for now but will need additional funding by late 2025 to support phase 3 trials. The company's valuation is high relative to its early-stage peers, but recent share price declines make it a "Hold" rather than a "Sell". Given the high risk and early data, I recommend a "Hold" rating unless you're highly risk-tolerant; the potential is strong but uncertain. Read the full article on Seeking Alpha
分析記事 • Mar 27

Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 02

ORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early Data

Summary ORIC Pharmaceuticals' ORIC-533 was promising but failed in trials, leaving ORIC-114 and ORIC-944 as key pipeline assets. ORIC-114 shows strong CNS penetration and promising results in brain metastasized NSCLC, with a significant market potential. ORIC-944, targeting prostate cancer, has shown encouraging efficacy and big pharma interest, but more data is needed. Despite promising early-stage data, ORIC remains in the high-risk phase 1 stage; more mature data is needed before committing. Read the full article on Seeking Alpha
分析記事 • Dec 12

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
分析記事 • Aug 21

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 29

ORIC Pharmaceuticals Stock: Too Early To Justify This Valuation

Summary ORIC Pharmaceuticals is developing agents to address resistance to approved cancer therapies, trading at a premium due to recent announcements. The pipeline includes ORIC-114 targeting EGFR/HER2 mutations, ORIC-944 for prostate cancer, and ORIC-533 for multiple myeloma. Financially stable with a long cash runway, but early efficacy data and hype surrounding ORIC stock warrant caution in investing. Read the full article on Seeking Alpha
Seeking Alpha • Jul 17

ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value

Summary ORIC Pharmaceuticals, Inc. expects updated results from the phase 1b study, using ORIC-114 for the treatment of patients with mutated NSCLC, in the 1st half of 2025. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; Still a good market opportunity to go after, even if only targeting mutant NSCLC patients. Collaboration supply agreements made with J&J and Bayer to advance ORIC-944 in combination with ERLEADA and NUBEQA for treatment of patients with mCRPC respectively. The company had cash of $331.5 million as of March 31st of 2024; Enough cash to fund its operations into late 2026. Read the full article on Seeking Alpha
分析記事 • May 08

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Mar 13

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

Summary ORIC Pharmaceuticals has reported positive preliminary results for three programs in its pipeline: ORIC-944, ORIC-114, and ORIC-533. ORIC-944, for the treatment of metastatic prostate cancer, is expected to initiate a combination study in the first half of 2024 and provide a program update in mid-2024. The global prostate cancer market size is projected to surpass $27.51 billion by 2032. ORIC had $235 million in cash as of December 31st, 2023. It believes that it has enough cash on hand to fund its operations into 2026. Read the full article on Seeking Alpha
分析記事 • Jan 18

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Sep 27

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Jun 14

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Jan 24

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 14

ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech

Summary Shares have fallen by around 80% over the past year. EGFR/HER2 exon 20 and PRC2 inhibitors offer potentially differentiated shots on goal with early data sets expected 1H 2023. Depth and experience of leadership team is a green flag (ex-Ignyta, Medivation, Genentech). ORIC is well-capitalized with Q2 cash position of $237.8M and valuation appears overly pessimistic at EV of negative $80M. ORIC is a Speculative Buy. Key risks include disappointing data for phase 1 readouts 1H 23, delays in the clinic and heavy competition in certain areas. Shares of ORIC Pharmaceuticals (ORIC) have fallen by over 80% since upsized IPO was priced at $16 in April of 2020. So far in 2022, share price has also experienced a dismal 80% decline. Back in March I sold my remaining shares for a 68% loss at $4.50 (still 50% higher than where they currently trade). However, I did highlight conviction-sized insider buying and reminded readers that I planned to revisit in a couple quarters when 2023 readouts were closer. As time has passed, I decided to check back in on the story and found the valuation to be incredibly pessimistic ($120M market capitalization versus estimated Q3 cash position of just over $200M). In other words, Mr. Market is stating that ORIC, with 3 clinical-stage programs in early phase 1b studies, is worth NEGATIVE $80M. These are not merely "me-too" assets, as their EGFR/HER2 exon-20 program is brain penetrant (can address CNS-metastases where approved agents lack activity). Likewise, the PRC2 program is targeting the EED subunit whereas predecessors have opted for the EZH2 subunit (plagued by tolerability issues) and management noted that certain subpopulations in prostate cancer could allow for accelerated approval should data warrant. The above to say, with the usual caveats, that I think we should dig deeper as the company would seem to be worth more than NEGATIVE $80M. Chart Finviz Figure 1: ORIC weekly chart (Source: Finviz) When looking at charts, clarity often comes from taking a look at distinct time frames in order to determine important technical levels and get a feel for what's going on. In the weekly chart above, the decline from highs above $40 to current $3 share price is quite sickening (appears as if the company has "flat-lined" and is a shell of its former self). Despite looking like a shell company, there is still a lot going on under the hood (three phase 1 studies with readouts coming 1H 23) and so my initial suggestion for risk-tolerant investors would be to accumulate a small to modestly sized position at current levels ahead of these events. Given the current macro environment and headwinds to both risk assets as well as biotech sector, purchases could be spaced out over a period of months (or even quarters) instead of all at once. Overview Founded in 2014 with headquarters in San Francisco (78 employees), ORIC Pharma currently sports enterprise value of ~NEGATIVE $80M and estimated Q3 cash position of $200M providing them operational runway into 2H 2024. Here are my notes from September's Wainwright webcast which provides an excellent overview of current operations: ORIC= Overcoming Resistance in Cancer and encompasses their mission statement. Pipeline is broad and consists of potential first-in-class drug candidates and they have 3 ongoing phase 1b single-agent studies focused on validated targets followed by a pipeline of preclinical programs (both internally sourced as well as via external business development). They ended Q2 with $238M in cash with expected operational runway into 2H 24 (over a year after 3 data readouts expected in the first half of 2023). Corporate website Figure 2: Pipeline (Source: corporate website) Leadership team is highly experienced, starting with preclinical research discovery capabilities led by CSO and team that previously worked together at Genentech. They also possess full development, clinical and regulatory capabilities led by CMO and team that worked together previously at Ignyta and Aragon. Finally, they have extensive business development and strategic inlicensing capabilities via a team that worked together previously at Medivation and Ignyta. Successful oncology business models of the past several years tended to focus on building pipeline via internal discovery efforts or via business development. However, ORIC has been able to take a "source agnostic" approach to building the pipeline where the best molecule wins (whether internally developed or externally sourced). ORIC-533 is an oral bioavailable CD73 inhibitor discovered internally, whereas ORIC-114 was sourced from South Korean company Voronoi in October of 2020 and ORIC-944 from Mirati Therapeutics in July of 2020. They have 3 ongoing phase 1b studies. Bar is set high for differentiation versus competitors. Lastly, newest program is first-in-class PLK4 inhibitor in lead optimization stage. Starting with ORIC-533, they believe the molecule is differentiated on two fronts (both preclinically as well as via clinical development plan as a single agent in multiple myeloma). Preclinically versus other small and large molecule inhibitors of CD73 (as well as A2A receptor programs), ORIC-533 showed higher potency in multiple models. Also, 533 differentiates in a high adenosine or high AMP environment as well (important given high levels of adenosine typically seen in tumor microenvironment). For multiple myeloma, last year they showed a variety of preclinical results supporting potential as a single agent followed by combination trials pending single agent activity. Key takeaway from data presented last year (ex vivo autologous patient level) was that ORIC-533 achieved 40% lysis in these models (compared favorably to other approved agents in same models like lenalidomide and bortezomib). In the current phase 1 study they are enrolling late-line MM patients (triple and quad-refractory) starting as single agent. If there is even modest activity (sounds like the bar is not being set high), they'd move into multiple combination cohorts. As far as they know, ORIC-533 is the only CD73 inhibitor being tested as a single agent in multiple myeloma. Wainwright webcast Figure 3: Activity of ORIC-533 in MM comparable to standard of care therapies (Source: Wainwright presentation) Moving on to ORIC-114, this is a brain-penetrant EGFR/HER2 exon-20 program. Management prioritized finding a molecule selective for exon-20 insertion mutations over wild type (been a challenge for other players in the field). Second, they wanted to see CNS activity given prevalence of CNS metastases in this population. This molecule was specifically optimized across selectivity and brain penetration (exquisitely clean). Two currently approved agents for exon-20 have tolerability issues as well as lack of CNS activity. For ORIC-144, potent tumor regression has been observed in multiple non small cell lung cancer EGFR insertion models without significant weight loss. Head-to-head preclinical studies were also performed and 144 compared favorably in terms of efficacy and selectivity/signs of potential toxicities. Wainwright webcast Figure 4: In vivo efficacy for ORIC-144 compares favorably to competitors (Source: Wainwright presentation) The most important thing to highlight is CNS activity, as leading agents don't address CNS mets (35% to 40% of these patients develop CNS mets). In vivo data versus TAK-788 and osimertinib (clinically active CNS compound) showed superiority for ORIC-144. HER2 is another indication of interest for ORIC-144, and benchmark data versus Seagen's (SGEN) HER2 inhibitor tucatinib demonstrated antitumor activity in intracranial HER2+ breast cancer model (outperforming tucatinib). This is important as 50% of HER2+ breast cancer patients develop brain metastases. Phase 1b study is enrolling patients with advanced solid tumors who have either EGFR or HER2 exon-20 alterations or HER2 amplification or overexpression. Unlike competitor phase 1 studies, they are allowing patients with active CNS mets (treated or untreated but asymptomatic). CEO notes that amivantamab from JNJ is a great drug, but the big difference is again they are a large molecule and excluding patients with CNS mets. Wainwright webcast Figure 5: Superior efficacy for ORIC-144 in intracranial EGFR mutant models (Source: Wainwright presentation) Lastly, for allosteric PRC2 inhibitor ORIC-944, CEO notes that the PRC2 complex is a validated target with approved agents for epithelial sarcoma and follicular lymphoma. There are two druggable subunits for this complex, with most companies approaching it via EZH2 (associated with poor tolerability or PK limitations). There is only one other EED inhibitor in oncology (MAK683 from Novartis). Work done by Mirati comparing ORIC-944 to tazmetostat in DLBCL shows the former outperforming the latter by a wide margin. In androgen-resistant prostate cancer models, ORIC-944 showed good tumor growth inhibition (79% to 86% whereas competitors have seen 40% to 45% TGI). Per CEO, phase 1 study is progressing well (enrolling metastatic prostate cancer patients that have failed one or more AR modulators and up to 2 bouts of chemotherapy). These are later line patients lacking great options available, and goal is looking at safety, PK and selection of recommended phase 2 dose (sounds like they are expecting less in terms of early activity). Interestingly, they aim to see subsets of patients or potential biomarkers that would allow for accelerated approval in certain (smaller but still sizeable) populations. Wainwright webcast Figure 6: Strong single agent activity observed for ORIC-944, significantly better than blockbuster drug enzalutamide (Source: Wainwright presentation) PLK4 inhibitor program is in lead optimization, with the rationale being that cells with TRIM37 amplification require PLK4 function for growth and survival. TRIM37 amplification occurs in 20% of breast cancer and 50% of neuroblastoma and has been associated with early relapse and poor prognosis. This represents a synthetic lethality approach. Other Information For the second quarter of 2022, the company reported cash and equivalents of $237.8M contrasting favorably to R&D expenses of $13.8M and G&A expenses of $6.9M. Management is guiding for operational runway into 2H 2024, which seems reasonable to my eyes. Accumulated deficit to date per 10-K filing is around $245M, a reasonable figure for a company founded in 2014. As for competition, I do think it's important to keep an eye on Novartis' PRC2 inhibitor MAK683. Per clinical trials gov website, DLBCL seems to be the lead indication on deck for them. However, the study design allows for evaluation in other advanced malignancies such as nasopharyngeal carcinoma ((NPC)), gastric cancer, prostate cancer or other advanced solid tumors for whom no further effective standard treatment is available. Thus, any positive data reported here would likely spark a sympathy move in shares of ORIC as well. ORIC's PRC2 inhibitor to my eyes could be its crown jewel asset out of the 3 drug candidates currently in human studies. As mentioned above, there are certain populations they could potentially pursue accelerated approval via use of biomarkers such as H3K27 trimethylation. In EGFR exon 20, I am most familiar with Cullinan Oncology's (CGEM) CLN-081, which was the recipient of co-develop deal with Taiho Oncology for $275M upfront (allows for 50/50 US share of profits). Contrast the size of the upfront payment alone to ORIC's negative EV. Core Biotech holding Blueprint Medicines (BPMC) also scooped up LNG-451 in 2021 for $250M upfront payment (this drug candidate is highly brain penetrant as well). I imagine that ORIC will have a hard time going up against such larger players including Takeda, but again showing early monotherapy activity in patients with brain metastases would still positively impact share price and sentiment which are at all-time lows. As for ORIC-533, I remain highly skeptical of the inroads they can make in the highly crowded field of multiple myeloma given the impressive efficacy of approved CAR-T treatments not to mention next-generation cell therapy pioneers behind them (see my previous piece on Arcellx). As for institutional investors of note, EcoR1 Capital owns an 8.8% stake and has been adding to its position. String of insider purchases back in Q2 of this year was also encouraging, with CEO Jacob Chacko buying over $2.6M worth of shares.
分析記事 • Oct 08

Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 11

ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09

ORIC Pharmaceuticals press release (NASDAQ:ORIC): Q2 GAAP EPS of -$0.51 beats by $0.09. Cash, cash equivalents and investments totaled $237.8 million
分析記事 • Jun 24

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Mar 08

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Nov 23

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Aug 05

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Apr 16

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Jan 01

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

株主還元

ORICUS BiotechsUS 市場
7D2.7%0.5%0.6%
1Y43.6%35.8%20.1%

業界別リターン: ORIC過去 1 年間で35.8 % の収益を上げたUS Biotechs業界を上回りました。

リターン対市場: ORIC過去 1 年間で20.1 % の収益を上げたUS市場を上回りました。

価格変動

Is ORIC's price volatile compared to industry and market?
ORIC volatility
ORIC Average Weekly Movement12.0%
Biotechs Industry Average Movement9.9%
Market Average Movement7.1%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.1%

安定した株価: ORICの株価は、 US市場と比較して過去 3 か月間で変動しています。

時間の経過による変動: ORICの weekly volatility ( 12% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
2014111Jacob Chackowww.oricpharma.com

臨床段階のバイオ医薬品会社であるORIC Pharmaceuticals, Inc.は、米国で癌の耐性メカニズムに対抗する治療法の発見と開発に取り組んでいる。同社の臨床段階にある製品候補には、現在フェーズ1b試験中の脳内浸透性の経口生物学的利用可能な不可逆的阻害剤であるエノザルチニブ（旧名ORIC-114）、エクソン20挿入変異に対して高い効力を示す上皮成長因子受容体（EGFR）エクソン20およびヒト上皮成長因子受容体2エクソン20を選択的に標的とするエノザルチニブ、および現在フェーズ1b試験中の前立腺がんに対するポリコンブ抑制複合体2のアロステリック阻害剤であるリンジメトスタット（旧名ORIC-944）がある。ORIC-944をAR阻害剤Nubeqaと組み合わせて評価するための臨床試験提携および供給契約をバイエルと締結しており、AR阻害剤Erleadaと組み合わせて評価するための臨床試験提携および供給契約をジョンソン・エンド・ジョンソンと締結している。同社は2014年に法人化され、カリフォルニア州サウスサンフランシスコに本社を置いている。

ORIC Pharmaceuticals, Inc. 基礎のまとめ

ORIC Pharmaceuticals の収益と売上を時価総額と比較するとどうか。
ORIC 基礎統計学
時価総額US$1.44b
収益（TTM）-US$140.35m
売上高(TTM)n/a
0.0x
P/Sレシオ
-10.2x
PER（株価収益率

ORIC は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
ORIC 損益計算書（TTM）
収益US$0
売上原価US$0
売上総利益US$0
その他の費用US$140.35m
収益-US$140.35m

直近の収益報告

Jun 30, 2026

次回決算日

該当なし

一株当たり利益（EPS）-1.35
グロス・マージン0.00%
純利益率0.00%
有利子負債／自己資本比率0%

ORIC の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/08/16 13:06
終値2026/08/14 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

ORIC Pharmaceuticals, Inc. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18

アナリスト機関
Colleen KusyBaird
Prakhar AgrawalCantor Fitzgerald & Co.
Yigal NochomovitzCitigroup Inc